GLOW Quick Start
GLOW is a single co-formulated blend of three tissue-repair compounds — BPC-157, GHK-Cu, and TB-500 — supplied as one product in both vial and nasal-spray formats. It is dosed as one product; the sections below break out how much of each component a standard dose delivers, based on the vial content.
This guide is an educational research reference. It does not diagnose, treat, or prescribe, and is not medical advice. Consult a licensed clinician before considering any compound.
GLOW Composition
Each GLOW vial contains 70 mg total in a 5:1:1 ratio. The blend is GHK-Cu-dominant by weight, which is why it is most associated with skin and tissue-quality research.
| Component | Vial content | Share of blend | Primary research focus |
|---|---|---|---|
| GHK-Cu | 50 mg | 71% | Skin / collagen remodeling |
| BPC-157 | 10 mg | 14% | Tendon / gut / vessel repair |
| TB-500 | 10 mg | 14% | Cell migration / soft tissue |
GLOW Dosing Protocols
The injectable and nasal-spray formats are documented as two separate protocols, both dosed once daily. Because GLOW is a fixed blend, one dose delivers all three components at the 5:1:1 ratio. The per-component amounts are shown in the next section.
Injection — Subcutaneous
| Band | Per dose | Frequency |
|---|---|---|
| Reference | 10 units (0.10 mL) | Once daily |
Nasal Spray
| Band | Per dose | # of sprays | Frequency |
|---|---|---|---|
| Reference | 2.1 mg blend | 3 sprays | Once daily |
Cycle planning typically mirrors the tissue-repair components: 4–6 week blocks with 2–4 week off-periods. No human cycling RCT exists for the blend.
Per-Component Dosage Breakdown
This is the dose of each individual compound a standard GLOW dose delivers, derived from the 70 mg vial content and the 5:1:1 ratio, with the typical standalone research range for context.
Injection — 10 units (0.10 mL) once daily
| Component | Per dose | Typical standalone | Assessment |
|---|---|---|---|
| GHK-Cu | 1.67 mg | 1–2 mg daily | In range |
| BPC-157 | 0.33 mg (330 mcg) | ~250 mcg | In range |
| TB-500 | 0.33 mg (330 mcg) | 2–2.5 mg / dose | Light (low maintenance level) |
Nasal Spray — 3 sprays once daily
| Component | Per spray | Per dose (3 sprays) | Standalone |
|---|---|---|---|
| GHK-Cu | 0.5 mg | 1.5 mg | 1–2 mg |
| BPC-157 | 0.1 mg | 0.3 mg (300 mcg) | ~250 mcg |
| TB-500 | 0.1 mg | 0.3 mg (300 mcg) | 2–2.5 mg |
GLOW Reconstitution Guide
Injection
| BAC | Conc. | 10 u dose |
|---|---|---|
| 3 mL | 23.3 mg/mL | 0.10 mL · 2.33 mg |
One reconstitution, one daily draw. Units are U-100.
Reconstitution steps
- Inspect the vial. Confirm label and intact powder (a blue tint from GHK-Cu is expected).
- Wipe the stoppers. Alcohol swab on both vials.
- Draw BAC water. 3 mL into the injectable vial.
- Inject down the wall. Release water slowly down the inside wall, not onto the powder.
- Swirl, do not shake. Roll gently until clear.
- Refrigerate. Store at 2–8 °C; do not freeze.
How to use the nasal spray
- Prime first use. Pump 2–3 sprays into a tissue until a fine, even mist appears.
- Position. Tilt the head slightly forward; insert the tip just inside one nostril, aimed slightly outward toward the ear — not at the septum.
- Spray and breathe. Press once while breathing in gently; do not sniff hard, which sends the solution down the throat instead of onto the mucosa.
- Alternate nostrils. For multi-spray doses, switch nostrils each spray to spread absorption and limit irritation.
- Count per the protocol. Use the sprays-per-dose shown above; if a dose isn't a whole number, round up.
- Between uses. Wipe the tip, recap, and refrigerate.
Why These Three Together
GLOW pairs three compounds with complementary tissue-repair mechanisms. GHK-Cu drives collagen and matrix remodeling, BPC-157 supports angiogenesis and gut/vascular repair, and TB-500 supports cell migration via actin regulation. The combination is a convenience format for tissue-quality research planning rather than a clinically validated fixed-dose drug.
GHK-Cu
Collagen/elastin synthesis and skin remodeling (dominant by weight).
BPC-157
Angiogenesis and gut/vessel repair signaling.
TB-500
Actin-mediated cell migration into injured tissue.
Open question
The blend has no dedicated human trial; rationale is component-level.
Who Should Avoid GLOW
Tested athletes
TB-500 is on the WADA Prohibited List; the blend is therefore prohibited in sport.
Active or prior cancer
Angiogenesis/proliferation pathways across components are a theoretical concern.
Copper-metabolism disorders
GHK-Cu adds copper; avoid in Wilson's disease.
Pregnancy & lactation
No human safety data.
GLOW Side Effects & Safety
Injection-site reactions
Redness or stinging; rotate sites. The GHK-Cu component can sting more than the others.
Combined profile
Side effects reflect all three components; review each component's page.
Copper exposure
GHK-Cu-dominant, so cumulative copper applies; off-periods are common.
Quality-control risk
Verify blend identity and purity against a Certificate of Analysis.
Storage & Handling
| State | Storage | Notes |
|---|---|---|
| Lyophilized (powder) | −20 °C long-term; fridge short-term | Blue tint from GHK-Cu is normal. |
| Reconstituted (liquid) | 2–8 °C | Use within ~3–4 weeks; do not freeze. |
| Appearance | Clear blue solution | Discard cloudy or particulate solutions. |
Frequently Asked Questions
Is GLOW three separate vials?
No. GLOW is a single co-formulated blend (one vial, 70 mg total, 5:1:1) supplied in vial and nasal-spray formats, dosed as one product.
How much of each compound does a dose deliver?
Injection (10 units once daily): GHK-Cu 1.67 mg, BPC-157 0.33 mg, TB-500 0.33 mg. Spray (3 sprays once daily): GHK-Cu 1.5 mg, BPC-157 0.3 mg, TB-500 0.3 mg. See the breakdown section.
How is GLOW reconstituted?
Injection: 70 mg in 3 mL BAC water → 23.3 mg/mL, dose 10 units (0.10 mL). Spray: 70 mg in 10 mL → 0.7 mg blend per spray, ~3 sprays per dose.
Why is the TB-500 amount lower than its standalone dose?
GLOW is GHK-Cu-led at 5:1:1, so the TB-500 share lands at a lighter maintenance level. Researchers wanting a fuller TB-500 dose sometimes add standalone TB-500.
Is this page medical advice?
No. It is an educational research reference and does not diagnose, treat, or prescribe. Consult a licensed clinician before considering any compound.
References
- Pickart L, Margolina A. Regenerative actions of the GHK-Cu peptide. Int J Mol Sci (2018).
- Sikiric P, et al. Stable gastric pentadecapeptide BPC 157. Curr Pharm Des (2011).
- Goldstein AL, et al. Thymosin β4 and tissue repair. Ann N Y Acad Sci (2012).
- Component-level dosing references compiled on the linked GHK-Cu, BPC-157, and TB-500 pages.